Myriad Genetics, Inc. (MYGN) financial statements (2021 and earlier)
Company profile
| Business Address |
320 WAKARA WAY SALT LAKE CITY, UT 84108 |
| State of Incorp. | DE |
| Fiscal Year End | June 30 |
| SIC | 2835 - In Vitro and In Vivo Diagnostic Substances (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 9/30/2020 TTM | 6/30/2020 | 6/30/2019 | 6/30/2018 | 6/30/2017 | 6/30/2016 | 6/30/2015 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 218 | 137 | 181 | 151 | 159 | 145 | |||
| Cash and cash equivalents | 164 | 93 | 111 | 102 | 69 | 64 | |||
| Short-term investments | 54 | 44 | 70 | 48 | 91 | 81 | |||
| Receivables | 71 | 139 | 102 | 111 | 95 | 88 | |||
| Inventory, net of allowances, customer advances and progress billings | 29 | 31 | 34 | 42 | 38 | 25 | |||
| Inventory | 29 | 31 | 34 | 42 | 38 | 25 | |||
| Prepaid expense | 25 | 0 | 4 | ||||||
| Deferred tax assets | ✕ | ✕ | 14 | ||||||
| Other undisclosed current assets | 14 | 17 | 9 | 13 | 18 | 13 | |||
| Total current assets: | 332 | 349 | 326 | 317 | 315 | 284 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 66 | ✕ | ✕ | ✕ | ✕ | ✕ | |||
| Property, plant and equipment | 37 | 57 | 43 | 51 | 58 | 67 | |||
| Long-term investments and receivables | 37 | 55 | 31 | 49 | 80 | 41 | |||
| Long-term investments | 37 | 55 | 31 | 49 | 80 | 41 | |||
| Intangible assets, net (including goodwill) | 933 | 1,102 | 774 | 808 | 423 | 370 | |||
| Goodwill | 328 | 417 | 319 | 316 | 195 | 177 | |||
| Intangible assets, net (excluding goodwill) | 605 | 685 | 455 | 492 | 228 | 193 | |||
| Other noncurrent assets | 5 | 5 | |||||||
| Deferred tax assets, net | ✕ | ✕ | (0) | ||||||
| Other undisclosed noncurrent assets | 0 | ||||||||
| Total noncurrent assets: | 1,073 | 1,214 | 848 | 907 | 566 | 483 | |||
| TOTAL ASSETS: | 1,405 | 1,563 | 1,174 | 1,224 | 881 | 766 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 98 | 112 | 94 | 88 | 71 | 105 | |||
| Accounts payable | 22 | 33 | 26 | 22 | 21 | 21 | |||
| Accrued liabilities | 76 | 79 | 68 | 66 | 50 | 46 | |||
| Employee-related liabilities | 34 | ||||||||
| Taxes payable | 4 | ||||||||
| Deferred revenue | 33 | ✕ | ✕ | ✕ | ✕ | ✕ | |||
| Business combination, contingent consideration, liability | 3 | 3 | 5 | 127 | |||||
| Deferred revenue and credits | ✕ | ✕ | ✕ | 3 | 2 | 2 | |||
| Contract with customer, liability | ✕ | ✕ | 2 | ✕ | ✕ | ✕ | ✕ | ||
| Other undisclosed current liabilities | 14 | 3 | (38) | ||||||
| Total current liabilities: | 147 | 118 | 102 | 218 | 72 | 69 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 281 | 234 | 9 | ||||||
| Long-term debt, excluding current maturities | 224 | 234 | 9 | ||||||
| Operating lease, liability | 57 | ✕ | ✕ | ✕ | ✕ | ✕ | |||
| Liabilities, other than long-term debt, including: | 35 | 8 | 6 | 7 | 18 | 14 | |||
| Deferred tax liabilities, net | ✕ | ✕ | 83 | 57 | 84 | 0 | |||
| Deferred income tax liabilities | 27 | ✕ | ✕ | ✕ | ✕ | ✕ | |||
| Liability, pension and other postretirement and postemployment benefits | 6 | 5 | |||||||
| Other liabilities | 4 | 8 | 6 | 7 | 12 | 9 | |||
| Business combination, contingent consideration, liability | 4 | 10 | 9 | 13 | |||||
| Other undisclosed liabilities, other than long-term debt | (93) | (67) | (98) | ||||||
| Other undisclosed noncurrent liabilities | 24 | 115 | 91 | 222 | 42 | 22 | |||
| Total noncurrent liabilities: | 339 | 356 | 107 | 229 | 60 | 35 | |||
| Total liabilities: | 486 | 474 | 209 | 447 | 132 | 104 | |||
| Stockholders' equity | |||||||||
| Stockholders' equity attributable to parent | 918 | 1,089 | 965 | 778 | 748 | 662 | |||
| Common stock | 1 | 1 | 1 | 1 | 1 | 1 | |||
| Additional paid in capital | 1,097 | 1,068 | 915 | 851 | 830 | 745 | |||
| Accumulated other comprehensive loss | (5) | (5) | (4) | (6) | (10) | (7) | |||
| Retained earnings (accumulated deficit) | (174) | 26 | 53 | (68) | (73) | (77) | |||
| Stockholders' equity attributable to noncontrolling interest | (0) | ||||||||
| Total stockholders' equity: | 918 | 1,089 | 965 | 778 | 748 | 662 | |||
| TOTAL LIABILITIES AND EQUITY: | 1,405 | 1,563 | 1,174 | 1,224 | 881 | 766 | |||
Income statement (P&L) ($ in millions)
| 9/30/2020 TTM | 6/30/2020 | 6/30/2019 | 6/30/2018 | 6/30/2017 | 6/30/2016 | 6/30/2015 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 639 | 851 | 773 | 771 | 754 | 723 | ||
| Revenue, net | ✕ | ✕ | ✕ | 771 | 754 | 723 | ||
| Cost of revenue | (111) | (130) | (30) | (145) | (133) | (133) | ||
| Gross profit: | 527 | 721 | 743 | 626 | 621 | 590 | ||
| Operating expenses | (759) | (714) | (624) | (551) | (430) | (499) | ||
| Other undisclosed operating income (loss) | (26) | (25) | 42 | |||||
| Operating income (loss): | (232) | 8 | 119 | 49 | 167 | 134 | ||
| Nonoperating income (expense) | 8 | (8) | (2) | (7) | 2 | 1 | ||
| Investment income, nonoperating | 3 | 3 | 2 | 1 | 1 | 0 | ||
| Other nonoperating income (expense) | 16 | 1 | (0) | (3) | 1 | 0 | ||
| Interest and debt expense | (11) | (12) | (3) | (1) | ||||
| Income (loss) from continuing operations before equity method investments, income taxes: | (234) | (12) | 114 | 42 | 169 | 135 | ||
| Other undisclosed income from continuing operations before income taxes | 11 | 3 | 1 | |||||
| Income (loss) from continuing operations before income taxes: | (223) | (12) | 117 | 43 | 169 | 135 | ||
| Income tax expense (benefit) | 24 | 4 | 14 | (21) | (44) | (55) | ||
| Income (loss) before gain (loss) on sale of properties: | (200) | (8) | 131 | 22 | 125 | 80 | ||
| Other undisclosed net income | 12 | |||||||
| Net income (loss): | (200) | 4 | 131 | 22 | 125 | 80 | ||
| Net income attributable to noncontrolling interest | 0 | 0 | 0 | 0 | ||||
| Net income (loss) available to common stockholders, diluted: | (200) | 5 | 131 | 22 | 125 | 80 | ||
Comprehensive Income ($ in millions)
| 9/30/2020 TTM | 6/30/2020 | 6/30/2019 | 6/30/2018 | 6/30/2017 | 6/30/2016 | 6/30/2015 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | (200) | 4 | 131 | 22 | 125 | 80 | ||
| Other comprehensive income (loss) | 4 | (3) | (6) | |||||
| Comprehensive income (loss): | (200) | 4 | 131 | 26 | 123 | 75 | ||
| Comprehensive income, net of tax, attributable to noncontrolling interest | 0 | 0 | 0 | 0 | ||||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | 0 | (1) | 2 | |||||
| Comprehensive income (loss), net of tax, attributable to parent: | (199) | 3 | 133 | 26 | 123 | 75 | ||
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.